Literature DB >> 21549149

HIV-1 nucleotide mixture detection in the virco(®)TYPE HIV-1 genotyping assay: a comparison between Sanger sequencing and 454 pyrosequencing.

Hans De Wolf1, Herwig Van Marck, Wendy Mostmans, Kim Thys, Ina Vandenbroucke, Veerle Van Eygen, Theresa Pattery, Peter Verhasselt, Jeroen Aerssens.   

Abstract

HIV-1 Protease (PR) and Reverse Transcriptase (RT) genotyping is well established for the management of antiretroviral (ARV) drug therapy, as it is able to detect gene mutations encoding resistance to ARV compounds or drug classes, that are associated with reduced drug susceptibility (i.e. phenotype). A correct phenotypic interpretation from the derived PR-RT genotype (i.e. virtual phenotype), requires a well characterized geno-phenotype correlative database and appropriate statistical predictive models. The applicability of the virtual phenotype for the patient, will, however, not only depend on the accuracy of the statistical models and the database they rely on, but also depend largely on the sequence information that is provided. Since HIV-1 evolves as a complex of closely related but non-identical viral genomes (i.e. quasispecies) it is crucial that the sequencing method used, is able to characterize most of the genetic mixtures that make up the different quasispecies within a single patient. US regulatory agencies require that developers of HIV-1 genotyping assays, determine and report the HIV-1 mixture detection level of their assay. Hence, the mixture scoring sensitivity of the population-based Sanger sequencing method, along with the defined mixture scoring rules, used to drive the virco(®)TYPE HIV-1 virtual phenotype, was investigated by comparing it to the 454 pyrosequencing technique, which is able to generate the complete viral population sequence. To this end the PR-RT coding sequence of 20 clinical isolates was determined by both sequencing methodologies. The genotyping assay which feeds the virco(®)TYPE HIV-1 virtual phenotype was able to call automatically 97.5% (i.e. 268 mixtures) and 95.3% (i.e. 326 mixtures) of the mixtures that were present between 25 and 75% and between 20 and 80% in the viral population, as detected by 454. From the not called mixtures, all but one did present a mixture sequence in the Sanger DNA chromatograms, however, with a peak surface area for the second peak that was below the threshold setting for automatic mixture calling in the basecaller software (i.e. 25%). Viral loads ranged from 470 to 629,000 copies/mL and exerted no effect on the mixture calling relationship between both sequencing methodologies (R(2)=0.92). In some occasions (i.e. 55 mixtures) the genotyping assay would detect automatically mixtures that were present below 20% in the viral population, when measured by 454. Hence, the mixture scoring sensitivity of the automated high throughput virco(®)TYPE HIV-1 genotyping assay is currently set at 97.5% and 95.3%, for mixtures present at 25 and 20% in the viral population and may identify occasionally mutations that are present at lower frequencies. These findings were not influenced by the viral load of the examined samples.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21549149     DOI: 10.1016/j.jviromet.2011.04.023

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  5 in total

1.  Ultra-Deep Sequencing Analysis on HIV Drug-Resistance-Associated Mutations Among HIV-Infected Individuals: First Report from the Philippines.

Authors:  Ivo N SahBandar; Genesis Samonte; Elizabeth Telan; Nalyn Siripong; Mahdi Belcaid; David Schanzenbach; Susan Leano; Haorile Chagan-Yasutan; Toshio Hattori; Cecilia M Shikuma; Lishomwa C Ndhlovu
Journal:  AIDS Res Hum Retroviruses       Date:  2017-07-05       Impact factor: 2.205

2.  Clinical implications of HIV-1 minority variants.

Authors:  Jonathan Z Li; Daniel R Kuritzkes
Journal:  Clin Infect Dis       Date:  2013-02-27       Impact factor: 9.079

3.  Comparison of Major and Minor Viral SNPs Identified through Single Template Sequencing and Pyrosequencing in Acute HIV-1 Infection.

Authors:  Shyamala Iyer; Eleanor Casey; Heather Bouzek; Moon Kim; Wenjie Deng; Brendan B Larsen; Hong Zhao; Roger E Bumgarner; Morgane Rolland; James I Mullins
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

4.  Contribution of human immunodeficiency virus type 1 minority variants to reduced drug susceptibility in patients on an integrase strand transfer inhibitor-based therapy.

Authors:  Richard M Gibson; Jan Weber; Dane Winner; Michael D Miller; Miguel E Quiñones-Mateu
Journal:  PLoS One       Date:  2014-08-11       Impact factor: 3.240

5.  Low-cost ultra-wide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance.

Authors:  Dawn M Dudley; Emily N Chin; Benjamin N Bimber; Sabri S Sanabani; Leandro F Tarosso; Priscilla R Costa; Mariana M Sauer; Esper G Kallas; David H O'Connor
Journal:  PLoS One       Date:  2012-05-04       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.